title: Etanercept treatment in Fanconi anaemia; combined US and Italian experience.
authors: Parinda A
authors: PA
authors: Mehta
authors: Johanna
authors: J
authors: Svahn
authors: Stella M
authors: SM
authors: Davies
authors: Qishen
authors: Q
authors: Pang
authors: Richard
authors: R
authors: Harris
authors: Pietro
authors: P
authors: Ghezzi
authors: Tiziana
authors: T
authors: Lanza
authors: Elisa
authors: E
authors: Ferretti
authors: Paola
authors: P
authors: Barabino
authors: Robin
authors: R
authors: Mueller
authors: Carlo
authors: C
authors: Dufour
mesh_terms: D000015:Abnormalities, Multiple; D000741:Anemia, Aplastic; D001855:Bone Marrow Diseases; D000080983:Bone Marrow Failure Disorders; D002648:Child; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D000068800:Etanercept; D005199:Fanconi Anemia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007558:Italy; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014481:United States; D055815:Young Adult
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept